The U.S. Justice Department, supported by attorneys general from four states, has moved to block UnitedHealth Group’s proposed $3.3 billion acquisition of Amedisys Inc., citing concerns over competition and patient care. The case underscores the Biden administration’s more aggressive stance on antitrust enforcement after decades of increasing corporate consolidation.
Amedisys Acquisition Sparks Antitrust Alarm
UnitedHealth Group, the fourth-largest U.S. corporation by revenue, already wields considerable influence across the healthcare landscape through its Optum division and its ownership of the LHC Group, a direct competitor to Amedisys. If the merger proceeds, the Justice Department warns, it could create a duopoly in the home health and hospice care market, reducing competition and ultimately harming patients and healthcare workers.
Attorney General Merrick Garland made the stakes clear in a public statement: “Patients and their families deserve affordable, high-quality care options during some of the hardest times of their lives. The Justice Department will not hesitate to challenge unlawful consolidation that threatens to harm vulnerable patients.”
UnitedHealth, however, argues that the merger would spur innovation and improve access to care. “We will vigorously defend against the Department of Justice’s overreaching interpretation of the antitrust laws,” the company said.
Document Concerns Raise the Stakes
Beyond the merger’s antitrust implications, the Justice Department has also accused Amedisys of failing to disclose critical documents during the review process. The allegations include millions of missing documents and possible deletions, violating the Antitrust Improvements Act of 1976. These actions could result in legal sanctions, adding another layer of scrutiny to the proposed deal.
The Bigger Picture: Healthcare Consolidation and Its Critics
The Amedisys case is part of a broader federal effort to curb the dominance of healthcare conglomerates. UnitedHealth’s OptumRx, along with CVS Caremark and Express Scripts, controls access to 80% of insured patients in the U.S. Critics claim these pharmacy benefit managers (PBMs) leverage their market power to secure hefty rebates from drugmakers while squeezing pharmacies with low reimbursement rates.
These practices, critics argue, have led to higher costs for consumers and forced many independent pharmacies out of business. In 2022, the Federal Trade Commission (FTC) launched an investigation into PBMs and released an interim report this year alleging their actions were inflating drug prices and harming patients.
Notable Antitrust Actions in Healthcare and Beyond
The Biden administration’s crackdown on corporate consolidation extends beyond healthcare:
- Insulin Pricing: The FTC filed a lawsuit in September accusing PBMs of practices that caused insulin prices to surge beginning in 2012.
- Grocery Industry: The FTC is suing to block the Kroger-Albertsons merger, arguing it would further reduce competition in the grocery sector.
- Entertainment & Payments: The Justice Department’s Antitrust Division is pursuing cases against Ticketmaster/Live Nation and Visa for monopolistic practices.
The Push for Consumer and Market Fairness
Jonathan Kanter, head of the Justice Department’s Antitrust Division, emphasized the impact of unchecked consolidation on American consumers. “Unless this $3.3 billion transaction is stopped, UnitedHealth Group will further extend its grip to home health and hospice care, threatening seniors, their families, and nurses,” he said.
Antitrust law in the U.S. historically sought to balance efficiency with fairness to consumers and smaller businesses. However, decades of prioritizing efficiency led to a wave of mergers, consolidating power in key industries. The current administration’s efforts signal a return to stricter antitrust enforcement, aiming to restore competitive markets and protect consumers.
Comments